Main
tumor
DISEASE PROGRESSION, TUMOR, CYTOTOXICITY
Mutations in the epidermal growth factor receptor (Based on next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) and tumor samples from patients who experience disease progression on osimertinib, identified mechanisms of resistance can be broadly divided into EGFR-dependent mechanisms (alterations preventing osimertinib inhibition of EGFR) and EGFR-independent mechanisms (activation of alternate signaling pathways or reprogramming, such as epithelial–mesenchymal transition and histologic transformations)Overcoming osimertinib resistance is further complicated by heterogeneous patterns of resistance and presence of co-occurring resistance mechanisms, which can occur even within a single patientAmivantamab is a fully human bispecific antibody that binds to the EGFR and MET receptor to inhibit ligand binding, promote downregulation of cell surface receptors and induce Fc-dependent trogocytosis and antibody-dependent cellular cytotoxicity